Calcium is the most abundant cation found in the human body and plays an integral role in neural transmission, enzyme activity, myocardial function, coagulation and other cellular functions. Most of the calcium is found in the bones as calcium phosphate while a small percentage is found in the cells and extracellular fluids. In the serum, about 45% of calcium is bound to proteins, 45% exists as free or ionized calcium, the active form, while 10% is bound to anions. Systemic acidosis decreases calcium binding to albumin increasing serum levels while alkalosis causes the opposite effect. Serum calcium concentrations are highest in neonates and infants, decrease during childhood and adolescence, and stabilize at adult values by 17 years of age. Hypercalcemia is defined as serum calcium concentration two standard deviations above the mean values. The normal serum calcium ranges from 8.8 mg/dL-10.8 mg/dL. Primary hyperparathyroidism and malignancy accounts for 90% of the cases of hypercalcemia. 
The main cause of hypercalcemia is an excess parathyroid hormone (PTH). PTH-mediated causes include adenoma/hyperplasia of the gland, familial hypocalciuric hypercalcemia, and multiple endocrine neoplasia syndromes (type1, 2A). Familial hypocalciuric hypercalcemia is an autosomal dominant condition due to an inactivating mutation in the calcium-sensing receptor gene.
Although more common in adults than pediatric patients, the next important etiology to consider is a malignancy. Renal carcinomas, leukemias, lymphomas, and rhabdomyosarcoma can be associated with elevated calcium levels mediated by the action of PTH-related peptides.
Hypervitaminosis D can be iatrogenic, secondary to excessive milk intake, or related to granulomatous conditions such as sarcoidosis, tuberculosis or fungal infections.
Endocrine causes such as thyrotoxicosis (due to stimulation of osteoclast function by thyroid hormone), hypoadrenalism and pheochromocytomas can be associated with hypercalcemia.
Other miscellaneous causes include Williams syndrome, Murk Jansen syndrome, hypophosphatasia, hypervitaminosis A, acute/chronic renal failure, use of thiazide diuretics or lithium, milk-alkali syndrome, subcutaneous fat necrosis, and prolonged immobilization. Williams-Beuren syndrome is characterized by elfin facies, subvalvular aortic stenosis, short stature, and developmental delay. Features of Murk Jansen syndrome include extreme short stature (short-limbed dwarfism), prominent eyes, high-arched palate, wide open fontanelles and micrognathia.
The prevalence of hypercalcemia in the general population is approximately 1% to 2%. Most of the cases (90%) of hypercalcemia are secondary to primary hyperparathyroidism and malignancy-associated hypercalcemia. The prevalence of primary hyperparathyroidism in the general population ranges from 0.2% to 0.8% and increases with age. Overall, 2% of all cancers are associated with hypercalcemia, but in the pediatric age group, the prevalence is about 0.4% to 1.3%.
Calcium concentration is regulated by plasma membrane calcium receptor, PTH and its receptor, calcitonin and its receptor, and by the actions of vitamin D on kidneys, bone, and intestines. PTH mobilizes calcium directly by enhancing bone resorption, and indirectly, by stimulating one alpha-hydroxylase which increases vitamin D3 production, in turn, leading to increased absorption of calcium from the gut and increased bone resorption. Primary hyperparathyroidism is due to a solitary adenoma or diffuse hyperplasia of the gland. In this condition, there is an abnormal set point in the relation between calcium and PTH levels and calcium-independent PTH secretion. Familial hypocalciuric hypercalcemia is inherited autosomal dominant pattern and is due to an inactivating mutation in the calcium-sensing receptor gene. Granulomatous lesions cause ectopic vitamin D production. Transient neonatal hypercalcemia can rarely be seen in infants born to mothers with hypoparathyroidism.
Hypercacemia from hyperparathyroidism is mild and could go one for years and be asymptomatic. Hypercalcemia from malignancy is assoicated with rapidly increasing calcium levels
Symptoms of hypercalcemia are usually seen when serum calcium levels are more than 12 mg/dl. Irrespective of the etiology, the broad signs and symptoms can be summarized as "groans, bones, stones, moans, thrones and psychic overtones".
Severe hypercalcemia inhibits neuromuscular and myocardial depolarization leading to muscle weakness and arrhythmias. Cardiovascular effects include prolonged PR interval, short QT interval, widened QRS complex, and bradycardia. Increased thirst with polydipsia and polyuria is seen initially, progressing to nephrolithiasis and nephrocalcinosis in chronic cases. Neurologic features include impaired concentration, altered mental status ranging from confusion to irritability. Levels of more than 14 mg/dL can cause encephalopathy and levels above 15 mg/dL is a medica emergency. Severe acute abdominal pain should be a clue to evaluate for pancreatitis. Osseous changes can lead to bone pain, gait abnormalities, and fractures and are seen radiologically as subperiosteal and endosteal bone resorption. In infants and young children, hypercalcemia can cause poor weight gain and failure to thrive.
Hypercalcemia can be calssified into
Most cases of hypercalcemia are detected on routine testing. Work up for etiology includes obtaining serum PTH, calcitonin, Vitamin D, ionized calcium, phosphorus, magnesium, alkaline phosphatase levels, renal functions, and urinary calcium-creatinine ratio. Sensitive and specific immunochemiluminometric assays should be used to measure parathyroid hormone (PTH) (i-PTH). Hyperparathyroidism is characterized by high calcium, high i-PTH levels with low phosphorous levels. Familial hypocalciuric hypercalcemia has inappropriately normal PTH levels with high magnesium and low calcium creatinine clearance. Other causes of hypercalcemia typically have low PTH levels. Patients with hypercalcemia and hypervitaminosis D have high serum concentrations of calcidiol, whereas, patients with a granulomatous disease have high levels of calcitriol. In patients with hypercalcemia associated with malignancy, the PTH-related peptide levels are elevated. Imaging is indicated to identify nephrolithiasis and nephrocalcinosis. Neonates and infants who are found to be hypercalcemic in the presence of dysmorphic features should prompt evaluation for Williams or Murk Jansen syndrome.
Treatment for hypercalcemia is required if the patient is symptomatic or if the calcium level is more than 15 mg/dL, even in asymptomatic patients. The goals of treating hypercalcemia include increased elimination from the extracellular fluid, reducing gastrointestinal (GI) absorption and decreasing bone resorption. Immediate therapy is directed at restoring intravascular volume and promoting calcium excretion in the urine with an infusion of 0.9% saline at twice the maintenance rate until any fluid deficit is replaced and diuresis occurs (urine output ≥ 200 mL/h to 300 mL/h). Hemodialysis is the treatment of choice to rapidly decrease serum calcium in patients with heart failure or renal insufficiency. Loop diuretics should be used with caution as even though they may enhance renal excretion, paradoxical hypercalcemia can occur due to bone resorption. Patients with hyperparathyroidism require surgical exploration and removal of the source of increased PTH secretion. Postoperatively, patients need to be monitored closely for development of hypocalcemia and tetany. Bisphosphonates such as etidronate, pamidronate, and alendronate are the drugs of choice for hypercalcemia of malignancy as they inhibit osteoclastic activity. Hypercalcemia associated with excess vitamin D can be treated with steroids as they inhibit one alpha-hydroxylase activity. Ketoconazole, an antifungal agent, has also been used in hypervitaminosis D as it inhibits 1-alpha hydroxylase activity. Hypercalcemia of immobilization can be prevented by encouraging activity as tolerated and adequate hydration.The specific cause of hypercalcemia needs to be identified, and treatment directed accordingly.
Hypercalcemia, when it occurs following a benign disorder, has a good prognosis but when the cause is secondary to a malignancy the prognosis is poor. Patients with hypercalcemia associated with a malignancy are often symptomatic and need frequent hospitalizations.
Hypercalcemia should be confirmed by taking into account the serum albumin level and measuring an ionized calcium level.
Hypercalcemia is not an uncommon presentation to the hospital. The severity of the symptoms are related to the speed of development and the concentration of calcium. This metabolic problem can present in many ways, and only a multidisciplinary approach can help make a prompt diagnosis. Without treatment, the condition carries a very high morbidity. Besides physicians, nurses play a vital role in the management of patients with hypercalcemia. Patients should be educated about hydration, changes in diet and limiting calcium intake. The patient and family should be told about the symptoms of hypercalcemia and when to seek assistance. The pharmacist should check the medications to ensure that the cause is not due to the drug. In addition. The patient should be educated about the compliance with the bisphosphonates. Finally, a dietitian should be consulted to educate the patient on what type of foods to avoid. (Level III)
The outcomes depend on the cause of hypercalcemia. When the condition is due to hyperparathyroidism, symptoms tend to be mild but are prolonged. The highest morbidity is due to bone wasting. Mild hypercalcemia does not lead to mortality. However, hypercalcemia from a malignant cause carries a grave prognosis. These patients need aggressive treatment and also require frequent admissions to the hospital. Finally, the morbidity from the malignancy associated hypercalcemia can be severe leading to many symptoms and a very poor quality of life. (Level V)
|||Bilezikian JP, Primary Hyperparathyroidism. The Journal of clinical endocrinology and metabolism. 2018 Jul 27 [PubMed PMID: 30060226]|
|||Carrick AI,Costner HB, Rapid Fire: Hypercalcemia. Emergency medicine clinics of North America. 2018 Aug [PubMed PMID: 30037441]|
|||Efthymiou C,Spyratos D,Kontakiotis T, Endocrine paraneoplastic syndromes in lung cancer. Hormones (Athens, Greece). 2018 Jul 2 [PubMed PMID: 29968234]|
|||Alon US, The Effects of Diuretics on Mineral and Bone Metabolism. Pediatric endocrinology reviews : PER. 2018 Mar [PubMed PMID: 29806749]|
|||Catalano A,Chilà D,Bellone F,Nicocia G,Martino G,Loddo I,Morabito N,Benvenga S,Loddo S, Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing? Journal of clinical [PubMed PMID: 30023309]|
|||Wagner J,Arora S, Oncologic Metabolic Emergencies. Hematology/oncology clinics of North America. 2017 Dec [PubMed PMID: 29078931]|
|||Reid L,Muthukrishnan B,Patel D,Crane M,Akyol M,Thomson A,Seckl JR,Gibb FW, Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centre's experience. Endocrine connections. 2018 Aug 23 [PubMed PMID: 30139819]|
|||Simm PJ,Biggin A,Zacharin MR,Rodda CP,Tham E,Siafarikas A,Jefferies C,Hofman PL,Jensen DE,Woodhead H,Brown J,Wheeler BJ,Brookes D,Lafferty A,Munns CF, Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. Journal of paediatrics and child health. 2018 Mar [PubMed PMID: 29504223]|
|||Mannstadt M,Bilezikian JP,Thakker RV,Hannan FM,Clarke BL,Rejnmark L,Mitchell DM,Vokes TJ,Winer KK,Shoback DM, Hypoparathyroidism. Nature reviews. Disease primers. 2017 Aug 31 [PubMed PMID: 28857066]|
|||Walker J, Diagnosis and management of patients with hypercalcaemia. Nursing older people. 2015 May [PubMed PMID: 25924757]|
|||Hoyoux C,Lombet J,Nicolescu CR, Malignancy-Induced Hypercalcemia-Diagnostic Challenges. Frontiers in pediatrics. 2017 [PubMed PMID: 29181374]|
|||Wood L,Jacobs P, Myeloma--the integral role played by the professional nurse. Curationis. 1989 Dec [PubMed PMID: 2632105]|
|||Mhaskar R,Kumar A,Miladinovic B,Djulbegovic B, Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane database of systematic reviews. 2017 Dec 18 [PubMed PMID: 29253322]|
|||Curtin M,Piggott RP,Murphy EP,Munigangaiah S,Baker JF,McCabe JP,Devitt A, Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team. Orthopaedic surgery. 2017 May; [PubMed PMID: 28544780]|